British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab

Echo Research and Practice

article

Bushra Rana¹  Rebecca Dobson²  Susannah Stanway³  Daniel X Augustine⁴  Thomas Ingram⁶  Liam Ring⁷  Stuart Rosen⁸  Chris Plummer⁹  Charlotte Manisty^1,10  Mark Harbinson^1,11  Vishal Sharma^1,12  Arjun K Ghosh^1,10  Keith Pearce^1,14  Alexander R Lyon²  David Adlam^1,15  Bonnie Ky^1,16  Tom Marwick^1,17  Martin Stout^1,14  Allan Harkness^1,18  Rick Steeds^1,19  Shaun Robinson^2,20  David Oxborough^2,21 

[1] Imperial College Healthcare NHS Trust;Liverpool Heart and Chest NHS Foundation Trust;Royal Marsden NHS Foundation Trust and Institute of Cancer Research;Department of Cardiology, Royal United Hospitals Bath NHS Foundation Trust;Department for Health, University of Bath;The Shrewsbury and Telford Hospital NHS Trust;West Suffolk NHS Foundation Trust;Royal Brompton and Harefield NHS Foundation Trust and Imperial College London;The Newcastle upon Tyne Hospitals NHS Foundation Trust;Barts Heart Centre, Barts Health NHS Trust;Belfast Health and Social Care Trust;Royal Liverpool and Broadgreen University Hospitals NHS Trust;Hatter Cardiovascular Research Institute, University College London and University College London Hospitals NHS Foundation Trust;University Hospital South Manchester NHS Foundation Trust;University Hospitals of Leicester NHS Trust;Perelman School of Medicine at the University of Pennsylvania;Baker Heart and Diabetes Institute;East Suffolk and North Essex NHS Foundation Trust;University Hospitals Birmingham NHS Foundation Trust;North West Anglia Foundation Trust;Liverpool John Moores University

关键词: anthracycline f echocardiography f guidelines f HER2 therapy f imaging;   

DOI  :  10.1530/ERP-21-0001

学科分类：内科医学

来源: Bioscientifica Ltd.

【 摘 要 】

The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.

【 授权许可】

CC BY|CC0